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INTRODUCTION {#jjns12252-sec-0005}
============

Introduction of human papilloma virus vaccination {#jjns12252-sec-0006}
-------------------------------------------------

Vaccines against the human papilloma virus (HPV) initially were introduced into public use with the 2006 European approval of the quadrivalent vaccine and the subsequent 2007 approval of the bivalent vaccine. In June, 2006, the Food and Drug Administration in the USA approved the quadrivalent vaccine and the Advisory Committee on Immunization Practices recommended routine HPV vaccination for girls (Markowitz *et al.*, [2007](#jjns12252-bib-0009){ref-type="ref"}). By August, 2014, 58 countries had introduced the HPV vaccine into their national immunization program (World Health Organization, [2014](#jjns12252-bib-0021){ref-type="ref"}). As of November, 2015, \>63 million and 19 million persons worldwide were estimated to have been vaccinated with the quadrivalent and bivalent vaccine, respectively (European Medicines Agency, [2015](#jjns12252-bib-0005){ref-type="ref"}).

These vaccines also were approved for use in Japan in October, 2009 for the bivalent vaccine and July, 2011 for the quadrivalent vaccine. After a HPV vaccine promotion campaign, the vaccines were included in the Japanese vaccination program for girls aged 12--16 years in April, 2013. Within 3 months of formal designation as a routine vaccine, however, the Ministry of Health, Labour and Welfare issued a nationwide notice to withhold recommending HPV vaccination in June, 2013 (Ministry of Health, Labour & Welfare, [2013](#jjns12252-bib-0010){ref-type="ref"}). The measures that were taken by the Japanese Government triggered domestic and international controversy.

Case reports of adverse events {#jjns12252-sec-0007}
------------------------------

Kinoshita *et al.* ([2014](#jjns12252-bib-0008){ref-type="ref"}) reported 40 girls who were aged 11--17 years developed several symptoms after HPV vaccination. The authors referred to these symptoms as "complex regional pain syndrome" (CRPS) and "postural orthostatic tachycardia syndrome" (POTS), which were interpreted as peripheral autonomic disorders. Nishioka, Yokota, and Matsumoto ([2014](#jjns12252-bib-0013){ref-type="ref"}) proposed the term "HPV vaccination‐associated neuroimmunopathic syndrome" (HANS) in order to refer to a variety of symptoms that occur after HPV vaccination and created preliminary diagnostic criteria in 2014 (Nishioka, Yokota, & Matsumoto, [2014](#jjns12252-bib-0013){ref-type="ref"}; Yokota, Kuroiwa, Nakamura, Nakajima, & Nishioka, [2015](#jjns12252-bib-0022){ref-type="ref"}). Doctors and researchers who have examined patients with post‐HPV vaccination symptoms highlighted characteristic symptoms. The reported serious adverse events included diverse, complex, multisystem symptoms, such as: seizures; impaired consciousness; systemic pain including headache, myalgia, arthralgia, back pain, and other pain; motor dysfunction such as paralysis, muscular weakness, exhaustion, and involuntary movement; autonomic symptoms including dizziness, hypotension, tachycardia, and diarrhoea; endocrine disorders such as menstrual abnormality and menorrhagia; severe photophobia and hyperacusis; sleep disorders; and higher brain dysfunction and cognitive impairments including impaired memory, disorientation, and poor concentration (Kinoshita *et al.*, 2014; Nishioka, Yokota, & Matsumoto, 2014; Yokota, Kuroiwa, Nakamura, Nakajima, & Nishioka, 2014). Many of these symptoms overlap with CRPS, POTS, chronic fatigue syndrome (CFS) and fibromyalgia syndrome. Furthermore, in some cases, these symptoms impaired learning ability and resulted in extreme fatigue and decreased motivation, having a negative impact on everyday life (Kinoshita *et al*., 2014).

Blitshteyn ([2014](#jjns12252-bib-0002){ref-type="ref"}) from the USA reported six patients who developed POTS following HPV vaccination. Brinth, Theibel, Pors, and Mehlsen ([2015](#jjns12252-bib-0003){ref-type="ref"}) from Denmark presented 53 patients with suspected side‐effects to the quadrivalent HPV vaccine and reported that all the patients had symptoms that were consistent with pronounced autonomic dysfunction.

In recent years, Ozawa, Hineno, Kinoshita, Ishihara, and Ikeda ([2017](#jjns12252-bib-0015){ref-type="ref"}) described a case series of Japanese girls who were affected by suspected HPV vaccine‐related symptoms. They concluded that HPV vaccination was related to the transiently high prevalence of multiple symptoms, including CRPS and autonomic and cognitive dysfunction. Furthermore, Chandler *et al.* ([2017](#jjns12252-bib-0004){ref-type="ref"}) published a novel approach to case series identification for thorough signal evaluation by using data‐driven exploratory cluster analysis of HPV vaccine adverse event reports. They reported that the proportional reporting ratio of the combination of adverse events terms (headache and dizziness with either syncope or fatigue), comparing HPV vaccine reports with non‐HPV vaccine reports was 2.44 (95% confidence interval \[CI\]: 2.07--2.89) based on adverse events cluster analysis using VigiBase, the World Health Organization\'s international database of suspected adverse drug reactions. Their analysis also revealed a large number of reports with a pattern of adverse events, including headache, dizziness, fatigue, and syncope and that these symptoms overlapped those that were reported in cases from the safety signals (POTS, CRPS, and CFS) in previous studies.

Epidemiological studies {#jjns12252-sec-0008}
-----------------------

Souayah *et al.* ([2011](#jjns12252-bib-0019){ref-type="ref"}), using data from the United States Vaccine Adverse Event Reporting System during 2006--2009, identified 69 reports of Guillain‐Barré syndrome (GBS) after quadrivalent HPV vaccination and estimated that the weekly reporting rate of post‐quadrivalent HPV vaccine GBS within the first 6 weeks (6.6 cases per 10 million) was higher than that of the general population (0.65--2.57 cases per 10 million). A large Scandinavian register‐based cohort study comparing almost 300,000 cases (received at least one dose of the quadrivalent HPV vaccine) and 700,000 controls found increased risk ratios (RRs) for three autoimmune manifestations: Behçet\'s syndrome, Raynaud\'s disease, and type 1 diabetes (Arnheim‐Dahlström, Pasternak, Svanström, Sparén, & Hviid, [2013](#jjns12252-bib-0001){ref-type="ref"}).

A large‐scale, self‐completed mail survey of adverse events experienced in 70,000 young women, the "Nagoya City Cervical Cancer Immunization Program Survey" (hereafter, referred to as "the Nagoya Survey"), was conducted in September, 2015. Nagoya City reported the totalized summary and presented the complete questionnaire survey data to the public. At present, these summary and complete data are disclosed and available at the website of Nagoya City (Health and Welfare Bureau, Nagoya City, [2016](#jjns12252-bib-0007){ref-type="ref"}). Suzuki and Hosono ([2018](#jjns12252-bib-0020){ref-type="ref"}) reported that none of the reported symptoms were significantly associated with increased odds of them occurring after the administration of the HPV vaccine based on the results of the Nagoya Survey. The safety issue of the HPV vaccine is still a controversy. The aim of this study was to assess the safety of HPV vaccines by using data from the Nagoya Survey.

Current status and issues {#jjns12252-sec-0009}
-------------------------

Although numerous case reports have suggested that HPV vaccines can cause serious side‐effects, as well as a number of safety signals that have emerged with HPV vaccination in epidemiological studies, these findings do not provide consistent evidence for a causal link. Despite the existence of independently clustered reports and safety signals, on November 26, 2015, the European Medicines Agency ([2015](#jjns12252-bib-0005){ref-type="ref"}) released a 40 page assessment report on the safety of HPV vaccines, which concluded that there was no evidence of an association between HPV vaccines and CRPS or POTS, based on the review carried out by the European Medicines Agency\'s Pharmacovigilance Risk Assessment Committee.

In Japan, after the suspension of the government\'s recommendation for HPV vaccination in June, 2013, the HPV vaccination rate in the target population plunged from 80% at its peak to \<1% (as of 2015, 0.1% in 12 year olds; 0.7% in 13 year olds) (Ministry of Health, Labour & Welfare, 2016a). As of February, 2016, \~3.39 million teenage girls have been vaccinated in Japan (Ministry of Health, Labour & Welfare, [2016b](#jjns12252-bib-0012){ref-type="ref"}).

METHODS {#jjns12252-sec-0010}
=======

Data source and variable selection for the analyses {#jjns12252-sec-0011}
---------------------------------------------------

The data source for this investigation was the dataset of the Nagoya Survey (Health & Welfare Bureau, Nagoya City, [2016](#jjns12252-bib-0007){ref-type="ref"}). According to Nagoya City, the study population consisted of women who were aged 15--21 years who were residents of Nagoya City. The questionnaire survey period was from September to November, 2015 and the response rate was 43.3%. The original data of the 275 questions from the 30,793 respondents are disclosed as a set of PDF files on the website of Nagoya City. Professor Okumura of Mie University voluntarily converted the PDFs into comma‐separated values (CSVs) and uploaded them onto his personal website (Okumura, [2018](#jjns12252-bib-0014){ref-type="ref"}). The authors downloaded the CSV data from his website and selected eight items for the analyses: age, individual HPV vaccine administration, the brand name of the HPV vaccine that was administered, time of the first HPV vaccination, the 24 symptoms experienced during the questionnaire survey period, onset time of each symptom, currently having symptoms and frequency ("always" or "sometimes"), and consultation with a doctor for the symptom(s). The authors verified the accuracy of the data and confirmed that it was reliable for analysis.

Determining the vaccinated cases and the unvaccinated controls {#jjns12252-sec-0012}
--------------------------------------------------------------

By using binary answers ("yes"/"no") for the question on individual HPV vaccine administration, the respondents were categorized into the "vaccinated case" group or the "unvaccinated control" group. The respondents who checked both choices or did not answer the question were included in the "unclear" group. However, after examination of the unclear group, some respondents in this group were reclassified into the vaccinated case group because they clearly answered the time of HPV vaccination or because they responded "unclear" for two or three of the three questions about the correct time of vaccination for the three doses of HPV vaccine.

Determining the events and elapsed time period from the first vaccination to symptom onset {#jjns12252-sec-0013}
------------------------------------------------------------------------------------------

This study constructed 24 event variables for the analyses that corresponded to the 24 symptoms that were investigated in the survey by editing the binary answers of "yes" or "no" for the question on a certain symptom that was experienced during the questionnaire survey period. For the answers of "yes," it was judged that the respondent experienced the symptom, while for the answers of "no," it was judged that she did not experience it. If the respondent checked both answers or did not check either answer, it was judged that the respondent\'s event was "uncertain." However, some events were changed from "uncertain" to "experienced" when the experiences could be confirmed because the onset time of the symptom, currently experiencing the symptom, or consultation with a doctor for symptom(s) was clearly described.

Events were excluded in the vaccinated case group in which the first HPV vaccination was administered after the onset time of the symptom because the causes are antecedent to the consequences. Therefore, these records were treated as vaccinated cases with no symptom. Consequently, the questionnaire survey period was defined differently between the vaccinated cases and the unvaccinated controls: the questionnaire survey period for the vaccinated cases was restricted to the post‐vaccination period, while the period for the unvaccinated controls was the complete period of the questionnaire survey period (from 12 years of age to the participant\'s age at September, 2015). Hereafter, the term "study period" is used instead of the term "questionnaire survey period" to refer to the periods that are common between the vaccinated cases and the unvaccinated controls in terms of the "risk period." The intervals between the time of the first HPV vaccination and the onset time of the symptom in each vaccinated case was calculated for the analyses.

Statistical analyses {#jjns12252-sec-0014}
--------------------

The data were summarized with descriptive statistics as the mean with standard deviation (SD) and the median with the interquartile range and the crude incidence odds were compared for the events between the vaccinated and the unvaccinated groups by unadjusted odds ratios (ORs) with 95% CIs.

Possible associations between HPV vaccination and each symptom were explored by fitting two multiple logistic regression models (models 1 and 2) with different covariates to the data to estimate the adjusted ORs with 95% CIs. The covariates that were used in model 1 were "vaccination" and "age" and those in model 2 were "vaccination" and "study period." Furthermore, to explore the interaction effect of vaccination and study period on symptom experience, a multiple logistic regression was used in model 3. The covariates that were used in model 3 were "vaccination," "study period," and the interaction covariate between vaccination and study period. A logistic regression also was used to test for an interaction between vaccination and age and for an interaction between vaccination and study period. The results of two‐sided testing was shown if necessary with *P*‐values, without adjusting for multiplicity. All the analyses were conducted by using R version 3.2.2 (R Core Team, [2015](#jjns12252-bib-0016){ref-type="ref"}).

Of the 30,279 women whose data on HPV vaccination were available, the data on age were available for 29,846 women. These data were included in multiple logistic regression model 1 and the age‐stratified analyses. Of these 29,846 women, the time of the first vaccination was available for 26,665 women, who were included in multiple logistic regression models 2 and 3.

The proportion of vaccinated cases varied according to age due to the change in Japanese public health policy regarding HPV vaccination. Thus, the impact of a healthy vaccine effect bias would have varied by age. The healthy vaccine effect is a form of selection bias in which healthier persons might be more likely to be vaccinated, leading to a subsequent decrease in the risk of adverse events after vaccination; this bias is more likely to occur the higher the vaccination rate (Fine & Chen, [1992](#jjns12252-bib-0006){ref-type="ref"}; Shrank, Patrick, & Brookhart, [2011](#jjns12252-bib-0018){ref-type="ref"}). Therefore, when comparing vaccinated cases with unvaccinated controls in the 17--21 year old group, in which the proportion of vaccinated women was \>70%, it was considered that the likelihood of a healthy vaccine effect bias was high. In contrast, the proportions of vaccinated women in the 15‐ and 16 year old groups were 15% and 50%, respectively; thus, it was assumed that the risk of the healthy vaccine effect bias was relatively low in these age groups. Additionally, the respondents in the 15--16 year old group had reached the age of the target population for HPV vaccination after the suspension of the government recommendation. Therefore, it was hypothesized that almost all the respondents in this age group did not receive HPV vaccination simply because they did not want to be vaccinated and not because of health issues, leading to the low vaccination rate (15%). Almost all the unvaccinated controls in this age group were expected to be averagely healthy women. Furthermore, most women in the vaccinated case group, irrespective of age, were generally considered to be healthy women because they were healthy vaccine users. In order to minimize the impact of healthy user bias, age‐stratified analyses (15‐, 16‐, 15--16‐, and 17--21 year old groups) were carried out and the vaccinated cases in all age groups (15--21 year old group) were compared with the unvaccinated controls in the 15--16 year old group.

This is an analytical study using data from open data sources. For this type of study, formal consent is not required.

RESULTS {#jjns12252-sec-0015}
=======

Characteristics of the study population {#jjns12252-sec-0016}
---------------------------------------

Table [1](#jjns12252-tbl-0001){ref-type="table"} summarizes the characteristics of all the participants involved in the present study. Overall, 30,793 women were included, comprising 21,034 vaccinated cases, 9245 unvaccinated controls (subtotal: 30,279), and 514 women for whom their vaccination status was unclear.

###### 

Participants' characteristics

  Variable                      N (%)                                                                                                      
  ----------------------------- -------------- ---------------- ---------------- -------------- -------- -------------- -------- --------- ---------
  Birth year                    Age (years)    Vaccinated       Unvaccinated     Unclear        Total                                      
  (*n* = 21,034)                (*n* = 9245)   (*n* = 514)      (*n* = 30,793)                                                             
  2000                          15             662              (14.6)           3761           (82.8)   121            (2.7)    4544      \(100\)
  1999                          16             2123             (50.1)           2038           (48.1)   80             (1.9)    4241      \(100\)
  1998                          17             3158             (70.2)           1260           (28.0)   83             (1.8)    4501      \(100\)
  1997                          18             3766             (84.0)           663            (14.8)   55             (1.2)    4484      \(100\)
  1996                          19             3725             (88.0)           452            (10.7)   58             (1.4)    4235      \(100\)
  1995                          20             3749             (88.7)           428            (10.1)   50             (1.2)    4227      \(100\)
  1994                          21             3565             (86.9)           496            (12.1)   41             (1.0)    4102      \(100\)
  Subtotal                      20,748         (68.4)           9098             (30.0)         488      (1.6)          30,334   \(100\)   
  Age unclear                   286            (62.3)           147              (32.0)         26       (5.7)          459      \(100\)   
  Total                         21,034         (68.3)           9245             (30.0)         514      (1.7)          30,793   \(100\)   
  Vaccine administered: N (%)   Vaccinated                                                                                                 
  (*n* = 20,748)                                                                                                                           
  Bivalent vaccine              13,319         (64.2)                                                                                      
  Quadrivalent vaccine          4214           (20.3)                                                                                      
  Unknown                       2895           (14.0)                                                                                      
  No answer                     320            (1.5)                                                                                       
  Total                         20,748         (100.0)                                                                                     
  Age (years)                   Vaccinated     Unvaccinated     Total                                                                      
  (*n* = 20,748)                (*n* = 9098)   (*n* = 29,846)                                                                              
  Minimum                       15.0           15.0             15.0                                                                       
  Maximum                       21.0           21.0             21.0                                                                       
  Mean (SD)                     18.6           (1.7)            16.5             (1.8)          18.0     (2.0)                             
  Median (IQR^a^)               19.0           (17.0--20.0)     16.0             (15.0--17.0)   18.0     (16.0--20.0)                      
  Study period (year)           Vaccinated     Unvaccinated                                                                                
  (*n* = 17,567)                (*n* = 9098)                                                                                               
  Minimum                       0.0            3.0                                                                                         
  Maximum                       6.0            9.0                                                                                         
  Mean (SD)                     3.9            (0.9)            4.5              (1.8)                                                     
  Median (IQR)                  4.0            (3.0--4.0)       4.0              (3.0--5.0)                                                

IQR, interquartile range; SD, standard deviation.

First, except for the 16 year old group, there was a significant imbalance in the numbers of vaccinated and unvaccinated women. When the proportions of the vaccinated women were compared stratified by age, the proportion in the 15 year old group (14.6%) was far less than that of the 16 year old group (50.1%) and the 17--21 year old group (\>70%). Second, there were threefold more women who had been administered the bivalent HPV vaccine than the quadrivalent HPV vaccine. Third, the unvaccinated controls tended to be younger than the vaccinated cases. The mean (SD) age was 18.6 (1.7) years for the vaccinated cases and 16.5 (1.8) years for the unvaccinated controls. Finally, the mean study period for the vaccinated cases (3.9 years) was 0.6 years shorter than that of the unvaccinated controls (4.5 years).

**P**ossible association between human papilloma virus vaccination and symptoms {#jjns12252-sec-0017}
-------------------------------------------------------------------------------

### *Unadjusted and age‐adjusted odds ratios in all age groups* {#jjns12252-sec-0018}

Table [2](#jjns12252-tbl-0002){ref-type="table"} shows the unadjusted and age‐adjusted ORs for all 24 symptoms among the 29,846 women. The vaccinated cases were slightly more likely than the unvaccinated controls to have experienced symptoms of memory impairment (unadjusted OR: 1.13 \[95% CI: 0.97--1.33\]), involuntary movement (OR: 1.32 \[95% CI: 0.98--1.78\]), walking disability (OR: 1.29 \[95% CI: 0.80--2.10\]), a sudden attack of muscle weakness (OR: 1.11 \[95% CI: 0.88--1.40\]), and weakness (OR: 1.12 \[95% CI: 0.91--1.38\]). Apart from these symptoms, the other symptoms demonstrated ORs of \<1 and most of them were statistically significant. In contrast, the multivariate analysis with the multiple logistic regression in model 1 (adjusted for age) demonstrated that the ORs for the symptoms of involuntary movement and weakness were \~1 (involuntary movement: OR: 1.05 \[95% CI: 0.76--1.48\] and weakness: OR: 1.05 \[95% CI: 0.83--1.34\]). Apart from these two symptoms, the other symptoms demonstrated ORs of \<1 and most of them were statistically significant. These results suggest that there was no association between HPV vaccination and the symptoms.

###### 

Age‐adjusted odds ratios (ORs) provided by model 1 for all age groups

  No.   Symptom                             Vaccinated   Unvaccinated   Unadjusted   Age‐adjusted[†](#jjns12252-note-0002){ref-type="fn"}  *P* [‡](#jjns12252-note-0003){ref-type="fn"}                                      
  ----- ---------------------------------- ------------ -------------- ------------ ------------------------------------------------------ ---------------------------------------------- ------ ------ ------ ------ ------ ------
  1     Menstrual abnormality                  3603         17,001         2309                              6696                          0.61                                           0.58   0.65   0.55   0.52   0.59   0.03
  2     Menorrhagia                            1142         19,427         560                               8434                          0.89                                           0.80   0.98   0.77   0.68   0.86   0.29
  3     Arthralgia                             1163         19,411         720                               8276                          0.69                                           0.63   0.76   0.67   0.60   0.75   0.00
  4     Severe headache                        1529         19,083         925                               8097                          0.70                                           0.64   0.76   0.66   0.60   0.73   0.00
  5     Lassitude                              1831         18,775         1037                              7984                          0.75                                           0.69   0.81   0.64   0.59   0.71   0.00
  6     Exhaustion                             1867         18,734         991                               8028                          0.81                                           0.74   0.88   0.71   0.64   0.77   0.00
  7     Impaired consciousness                 1159         19,425         723                               8294                          0.68                                           0.62   0.75   0.67   0.60   0.75   0.00
  8     Abnormal visual field                  324          20,256         172                               8845                          0.82                                           0.68   0.99   0.68   0.55   0.85   0.01
  9     Severe photophobia                     720          19,881         356                               8662                          0.88                                           0.77   1.00   0.74   0.64   0.86   0.00
  10    Reduced visual acuity                  919          19,670         794                               8221                          0.48                                           0.44   0.53   0.52   0.46   0.58   0.00
  11    Dizziness                              1836         18,759         1089                              7927                          0.71                                           0.66   0.77   0.67   0.61   0.73   0.00
  12    Cold sensation in the legs             1775         18,807         1144                              7873                          0.65                                           0.60   0.70   0.55   0.50   0.60   0.06
  13    Sleep disorder                         1226         19,372         692                               8320                          0.76                                           0.69   0.84   0.57   0.51   0.64   0.00
  14    Hypersomnolence                        1936         18,632         1058                              7955                          0.78                                           0.72   0.85   0.69   0.63   0.76   0.00
  15    Skin roughness                         1497         19,100         1062                              7950                          0.59                                           0.54   0.64   0.54   0.49   0.59   0.89
  16    Hyperpnea                              536          20,075         335                               8694                          0.69                                           0.60   0.80   0.60   0.51   0.70   0.00
  17    Memory impairment                      559          20,054         217                               8805                          1.13                                           0.97   1.33   0.87   0.72   1.04   0.00
  18    Dyscalculia                            167          20,442          79                               8940                          0.92                                           0.71   1.21   0.61   0.45   0.83   0.00
  19    Dyslexia                               386          20,224         181                               8846                          0.93                                           0.78   1.11   0.66   0.54   0.81   0.00
  20    Involuntary movement                   175          20,436          58                               8964                          1.32                                           0.98   1.78   1.05   0.76   1.48   0.04
  21    Walking disability                      65          20,540          22                               8990                          1.29                                           0.80   2.10   0.90   0.53   1.57   0.06
  22    Using a cane or wheelchair              26          20,581          16                               8994                          0.71                                           0.38   1.32   0.49   0.25   1.02   0.26
  23    Sudden attack of muscle weakness       253          20,340         100                               8909                          1.11                                           0.88   1.40   0.92   0.71   1.20   0.01
  24    Weakness                               318          20,224         124                               8862                          1.12                                           0.91   1.38   1.05   0.83   1.34   0.06

Logistic regression in model 1;

*P*‐value: test for the interaction between vaccination and age.

CI, confidence interval.

When considering these age‐adjusted results, two key assumptions of multiple linear regression model 1 should be noted; that is, linearity and similarity (no interaction among the covariates). First, logistic regression model 1 assumes linearity of the independent variables and log odds of event occurrence. There were, however, no linear or monotone associations between age and the events across different symptoms in the total cohort. That is, the event rates did not show a tendency to increase or decrease relative to an increase of age. Furthermore, a substantial difference was observed between the event rates in the older age groups (e.g. ≥17 years or ≥18 years) and those in the younger age groups for several symptoms. For example, the event rates in the 15--16 year old group (or 15--17 year old group) were lower than those in the ≥17 year old group (or ≥18 year old group). A representative example of age‐stratified event rates in which the event rates in the 15--16 year old group were substantially lower than those in the ≥17 year old group is shown in Figure [1](#jjns12252-fig-0001){ref-type="fig"}. These findings suggest that not only with non‐linearity, but the population characteristics of the younger age groups, are substantially different from those of the older age groups related to discontinuity of the event rates.

![Age‐stratified event rates in all age groups: Memory impairment.](JJNS-16-433-g001){#jjns12252-fig-0001}

Second, it should be noted that an age‐adjusted rate is a method to make fairer comparisons between groups with different age distributions. This method assumes that the effect of age on an event rate is similar between groups or shows no significant interaction among the covariates. However, this similarity was not observed between the vaccinated cases and the unvaccinated controls. For instance, a weak linear trend between age and event rates was observed only in the unvaccinated controls for some symptoms and was not observed in the vaccinated cases across different symptoms. Examples of each group were shown by using the data on memory impairment. Whereas, a linear trend is not observed in the vaccinated cases, it was observed in the unvaccinated controls (Figs [2](#jjns12252-fig-0002){ref-type="fig"} and [3](#jjns12252-fig-0003){ref-type="fig"}), suggesting that the effect of age on the event rates is not similar between the two groups. Furthermore, as shown in Figure [1](#jjns12252-fig-0001){ref-type="fig"}, the event rates in the 15--16 year old group were substantially lower than those in the ≥17 year old group (Fig. [3](#jjns12252-fig-0003){ref-type="fig"}).

![Age‐stratified event rates in the vaccinated cases: Memory impairment.](JJNS-16-433-g002){#jjns12252-fig-0002}

![Age‐stratified event rates in the unvaccinated controls: Memory impairment.](JJNS-16-433-g003){#jjns12252-fig-0003}

Given these findings, it appeared that multiple logistic regression model 1, with age as a covariate, was not appropriate for the data analysis in the present study. In fact, the test for the interaction between vaccination and age was statistically significant, except for distinct symptoms: menorrhagia (*P* = 0.29), a cold sensation in the legs (*P* = 0.06), skin roughness (*P* = 0.89), walking disability (*P* = 0.06), using a cane or wheelchair (*P* = 0.26), and weakness (*P* = 0.06) (Table [2](#jjns12252-tbl-0002){ref-type="table"}). These results further support that model 1, with age as the covariate, was not appropriate.

### *Unadjusted and study period‐adjusted odds ratios in all age groups* {#jjns12252-sec-0019}

From the above‐mentioned findings, it was considered that an alternative covariate should be used in place of age for the logistic regression models. Therefore, "study period"‐adjusted ORs were estimated in model 2. Table [3](#jjns12252-tbl-0003){ref-type="table"} shows the study period‐adjusted ORs for all 24 symptoms among 26,665 women. The vaccinated cases were more likely than the unvaccinated controls to have experienced symptoms of memory impairment (OR: 1.23 \[95% CI: 1.03--1.47\]), dyscalculia (OR: 1.13 \[95% CI: 0.83--1.54\]), involuntary movement (OR: 1.53 \[95% CI: 1.11--2.13\]), walking disability (OR: 1.68 \[95% CI: 0.98--3.00\]), a sudden attack of muscle weakness (OR: 1.18 \[95% CI: 0.92--1.53\]), and weakness (OR: 1.21 \[95% CI: 0.97--1.52\]). Among these symptoms, the ORs of memory impairment and involuntary movement were statistically significant, suggesting that there is an association between HPV vaccination and these symptoms. The test for the interaction between vaccination and the study period was statistically significant for only seven symptoms (Table [3](#jjns12252-tbl-0003){ref-type="table"}).

###### 

Study period‐adjusted odds ratios (ORs) provided by model 2 in all age groups

  No.   Symptom                             Vaccinated   Unvaccinated   Unadjusted   Study period‐adjusted[†](#jjns12252-note-0005){ref-type="fn"}  *P* [‡](#jjns12252-note-0006){ref-type="fn"}                                      
  ----- ---------------------------------- ------------ -------------- ------------ --------------------------------------------------------------- ---------------------------------------------- ------ ------ ------ ------ ------ ------
  1     Menstrual abnormality                  2686         14,759         2309                                  6696                               0.53                                           0.50   0.56   0.55   0.52   0.59   0.90
  2     Menorrhagia                            871          16,544         560                                   8434                               0.79                                           0.71   0.88   0.85   0.76   0.95   0.56
  3     Arthralgia                             894          16,529         720                                   8276                               0.62                                           0.56   0.69   0.65   0.58   0.72   0.07
  4     Severe headache                        1166         16,294         925                                   8097                               0.63                                           0.57   0.69   0.67   0.61   0.74   0.54
  5     Lassitude                              1396         16,058         1037                                  7984                               0.67                                           0.61   0.73   0.72   0.66   0.79   0.00
  6     Exhaustion                             1436         16,011         991                                   8028                               0.73                                           0.67   0.79   0.77   0.71   0.85   0.01
  7     Impaired consciousness                 903          16,532         723                                   8294                               0.63                                           0.57   0.69   0.65   0.59   0.73   0.22
  8     Abnormal visual field                  255          17,176         172                                   8845                               0.76                                           0.63   0.93   0.85   0.69   1.04   0.17
  9     Severe photophobia                     550          16,899         356                                   8662                               0.79                                           0.69   0.91   0.89   0.77   1.02   0.40
  10    Reduced visual acuity                  677          16,763         794                                   8221                               0.42                                           0.38   0.46   0.42   0.38   0.47   0.29
  11    Dizziness                              1417         16,025         1089                                  7927                               0.64                                           0.59   0.70   0.66   0.61   0.72   0.01
  12    Cold sensation in the legs             1331         16,101         1144                                  7873                               0.57                                           0.52   0.62   0.61   0.56   0.66   0.33
  13    Sleep disorder                         940          16,508         692                                   8320                               0.68                                           0.62   0.76   0.78   0.70   0.87   0.11
  14    Hypersomnolence                        1493         15,925         1058                                  7955                               0.70                                           0.65   0.77   0.75   0.69   0.82   0.14
  15    Skin roughness                         1171         16,272         1062                                  7950                               0.54                                           0.49   0.59   0.56   0.51   0.61   0.77
  16    Hyperpnea                              408          17,049         335                                   8694                               0.62                                           0.54   0.72   0.71   0.61   0.83   0.96
  17    Memory impairment                      437          17,022         217                                   8805                               1.04                                           0.88   1.23   1.23   1.03   1.47   0.00
  18    Dyscalculia                            133          17,321          79                                   8940                               0.87                                           0.66   1.15   1.13   0.83   1.54   0.00
  19    Dyslexia                               291          17,163         181                                   8846                               0.83                                           0.69   1.00   1.00   0.82   1.22   0.00
  20    Involuntary movement                   150          17,307          58                                   8964                               1.34                                           0.99   1.82   1.53   1.11   2.13   0.12
  21    Walking disability                      54          17,397          22                                   8990                               1.27                                           0.77   2.08   1.68   0.98   3.00   0.34
  22    Using a cane or wheelchair              21          17,433          16                                   8994                               0.68                                           0.35   1.30   0.90   0.44   1.90   0.91
  23    Sudden attack of muscle weakness       208          17,234         100                                   8909                               1.08                                           0.85   1.37   1.18   0.92   1.53   0.01
  24    Weakness                               276          17,134         124                                   8862                               1.15                                           0.93   1.43   1.21   0.97   1.52   0.22

Logistic regression in model 2;

*P*‐value: test for the interaction between vaccination and the study period.

CI, confidence interval.

However, it should be noted that linearity was observed between event rates and the study period within only some symptoms. An example of a vaccinated case group was shown by using the data on memory impairment, in which a linear trend was not observed (Fig. [4](#jjns12252-fig-0004){ref-type="fig"}). The study period‐stratified event rates in the unvaccinated controls were the same as the age‐stratified event rates in the unvaccinated controls, as shown in Figure [3](#jjns12252-fig-0003){ref-type="fig"}. Therefore, it is suggested that the effect of the study period on event rates is not similar between the two groups.

![Study period‐stratified event rates in the vaccinated cases: Memory impairment.](JJNS-16-433-g004){#jjns12252-fig-0004}

These findings suggest that logistic regression model 2, with the study period as the covariate, does not always fit the data for the analyses and other approaches should be designed. Therefore, the results of both model 1 (age‐adjusted) and model 2 (study period‐adjusted) are considered as preliminary data.

Additionally, the study‐period adjusted ORs were estimated in model 3. By fitting multiple logistic regression model 3, of the seven symptoms in which the test for an interaction between vaccination and the study period was statistically significant, four symptoms demonstrated ORs that were \>1 with statistical significance. They were the symptoms of memory impairment (OR: 3.59 \[95% CI: 2.05--6.25\]), dyscalculia (OR: 4.37 \[95% CI: 1.63--11.61\]), dyslexia that was characterized by a difficulty in reading and writing Chinese characters (hereinafter, referred to as "dyslexia") (OR: 2.82 \[95% CI: 1.46--5.39\]), and a sudden attack of muscle weakness (OR; 3.16 \[95% CI: 1.42--6.96\]), suggesting that there is an association between HPV vaccination and these symptoms (Table [4](#jjns12252-tbl-0004){ref-type="table"}).

###### 

Study period‐adjusted odds ratios (OR)s provided by model 3 in all age groups

  No.   Symptom                             Vaccinated   Unvaccinated   Unadjusted   Study period‐adjusted[†](#jjns12252-note-0008){ref-type="fn"}  *P* [‡](#jjns12252-note-0009){ref-type="fn"}                                       
  ----- ---------------------------------- ------------ -------------- ------------ --------------------------------------------------------------- ---------------------------------------------- ------ ------ ------ ------ ------- ------
  1     Menstrual abnormality                  2686         14,759         2309                                  6696                               0.53                                           0.50   0.56   0.54   0.43   0.68    0.90
  2     Menorrhagia                            871          16,544         560                                   8434                               0.79                                           0.71   0.88   0.76   0.51   1.12    0.56
  3     Arthralgia                             894          16,529         720                                   8276                               0.62                                           0.56   0.69   0.89   0.62   1.28    0.07
  4     Severe headache                        1166         16,294         925                                   8097                               0.63                                           0.57   0.69   0.61   0.44   0.84    0.54
  5     Lassitude                              1396         16,058         1037                                  7984                               0.67                                           0.61   0.73   1.27   0.94   1.70    0.00
  6     Exhaustion                             1436         16,011         991                                   8028                               0.73                                           0.67   0.79   1.12   0.83   1.51    0.01
  7     Impaired consciousness                 903          16,532         723                                   8294                               0.63                                           0.57   0.69   0.81   0.56   1.16    0.22
  8     Abnormal visual field                  255          17,176         172                                   8845                               0.76                                           0.63   0.93   1.34   0.67   2.65    0.17
  9     Severe photophobia                     550          16,899         356                                   8662                               0.79                                           0.69   0.91   1.08   0.66   1.74    0.40
  10    Reduced visual acuity                  677          16,763         794                                   8221                               0.42                                           0.38   0.46   0.34   0.23   0.51    0.29
  11    Dizziness                              1417         16,025         1089                                  7927                               0.64                                           0.59   0.70   0.98   0.73   1.30    0.01
  12    Cold sensation in the legs             1331         16,101         1144                                  7873                               0.57                                           0.52   0.62   0.70   0.52   0.95    0.33
  13    Sleep disorder                         940          16,508         692                                   8320                               0.68                                           0.62   0.76   1.04   0.72   1.50    0.11
  14    Hypersomnolence                        1493         15,925         1058                                  7955                               0.70                                           0.65   0.77   0.93   0.69   1.24    0.14
  15    Skin roughness                         1171         16,272         1062                                  7950                               0.54                                           0.49   0.59   0.53   0.39   0.73    0.77
  16    Hyperpnea                              408          17,049         335                                   8694                               0.62                                           0.54   0.72   0.70   0.40   1.21    0.96
  17    Memory impairment                      437          17,022         217                                   8805                               1.04                                           0.88   1.23   3.59   2.05   6.25    0.00
  18    Dyscalculia                            133          17,321          79                                   8940                               0.87                                           0.66   1.15   4.37   1.63   11.61   0.00
  19    Dyslexia                               291          17,163         181                                   8846                               0.83                                           0.69   1.00   2.82   1.46   5.39    0.00
  20    Involuntary movement                   150          17,307          58                                   8964                               1.34                                           0.99   1.82   3.19   1.17   8.66    0.12
  21    Walking disability                      54          17,397          22                                   8990                               1.27                                           0.77   2.08   3.68   0.66   20.66   0.34
  22    Using a cane or wheelchair              21          17,433          16                                   8994                               0.68                                           0.35   1.30   0.77   0.06   8.85    0.91
  23    Sudden attack of muscle weakness       208          17,234         100                                   8909                               1.08                                           0.85   1.37   3.16   1.42   6.96    0.01
  24    Weakness                               276          17,134         124                                   8862                               1.15                                           0.93   1.43   1.83   0.90   3.70    0.22

Logistic regression in model 3;

*P*‐value: test for the interaction between vaccination and the study period.

CI, confidence interval.

### *Unadjusted odds ratios provided by age‐stratified analyses (15‐, 16‐, 15--16‐, and 17--21 year old groups)* {#jjns12252-sec-0020}

The unadjusted ORs for the age‐stratified analyses of all 24 symptoms among the 29,846 women are shown in Table [5](#jjns12252-tbl-0005){ref-type="table"}. In the 15 year old group, the ORs were significantly higher for the symptoms of memory impairment (OR: 2.23 \[95% CI: 1.37--3.63\]), dyscalculia (OR: 2.30 \[95% CI: 1.01--5.24\]), and dyslexia (OR: 1.75 \[95% CI: 1.01--3.03\]). In the 15--16 year old group, the ORs were significantly higher for the symptoms of memory impairment (OR: 1.70 \[95% CI: 1.24--2.33\]), dyscalculia (OR: 1.77 \[95% CI: 1.00--3.13\]), and involuntary movement (OR: 1.86 \[95% CI: 1.07--3.23\]). In contrast, a subgroup analysis of the 17--21 year old group demonstrated the ORs of all symptoms were \<1 and most were statistically significant.

###### 

Unadjusted odds ratios (ORs) stratified by age group

                                          Age group (years)                                                                         
  ---- ---------------------------------- ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  1    Menstrual abnormality              0.68                0.55   0.85   0.57   0.49   0.66   0.60   0.54   0.68   0.55   0.51   0.60
  2    Menorrhagia                        0.91                0.62   1.33   0.77   0.58   1.01   0.83   0.67   1.02   0.77   0.67   0.90
  3    Arthralgia                         0.77                0.55   1.08   0.83   0.64   1.08   0.76   0.62   0.91   0.60   0.52   0.68
  4    Severe headache                    0.85                0.62   1.16   0.61   0.49   0.76   0.71   0.59   0.84   0.60   0.53   0.68
  5    Lassitude                          0.93                0.69   1.25   0.74   0.60   0.91   0.83   0.71   0.98   0.58   0.52   0.65
  6    Exhaustion                         1.00                0.75   1.33   0.76   0.62   0.94   0.87   0.74   1.03   0.65   0.58   0.73
  7    Impaired consciousness             0.84                0.60   1.19   0.76   0.59   0.97   0.81   0.67   0.98   0.57   0.50   0.65
  8    Abnormal visual field              1.06                0.57   1.97   1.04   0.60   1.79   0.90   0.62   1.32   0.63   0.49   0.81
  9    Severe photophobia                 0.73                0.43   1.23   1.03   0.72   1.47   0.89   0.68   1.17   0.67   0.56   0.79
  10   Reduced visual acuity              0.39                0.26   0.59   0.69   0.54   0.87   0.59   0.49   0.71   0.49   0.42   0.56
  11   Dizziness                          0.75                0.56   1.00   0.74   0.60   0.91   0.74   0.63   0.87   0.62   0.55   0.69
  12   Cold sensation in the legs         0.59                0.43   0.81   0.55   0.44   0.68   0.58   0.49   0.69   0.55   0.49   0.62
  13   Sleep disorder                     0.92                0.65   1.30   0.76   0.57   1.01   0.75   0.61   0.92   0.57   0.50   0.65
  14   Hypersomnolence                    0.86                0.64   1.15   0.67   0.54   0.82   0.78   0.66   0.91   0.68   0.61   0.76
  15   Skin roughness                     0.63                0.46   0.85   0.55   0.44   0.69   0.56   0.47   0.66   0.55   0.49   0.62
  16   Hyperpnea                          0.91                0.53   1.55   0.74   0.52   1.07   0.85   0.64   1.13   0.50   0.42   0.60
  17   Memory impairment                  2.23                1.37   3.63   1.66   1.04   2.66   1.70   1.24   2.33   0.68   0.56   0.83
  18   Dyscalculia                        2.30                1.01   5.24   2.25   0.86   5.87   1.77   1.00   3.13   0.50   0.36   0.68
  19   Dyslexia                           1.75                1.01   3.03   1.16   0.68   2.01   1.20   0.84   1.74   0.61   0.49   0.76
  20   Involuntary movement               0.95                0.28   3.23   2.25   1.03   4.93   1.86   1.07   3.23   0.89   0.60   1.31
  21   Walking disability                 1.90                0.38   9.45   1.60   0.38   6.70   1.62   0.60   4.36   0.81   0.45   1.49
  22   Using a cane or wheelchair         0.00                N/A    N/A    0.96   0.14   6.82   0.60   0.12   2.87   0.49   0.23   1.05
  23   Sudden attack of muscle weakness   0.86                0.34   2.21   1.45   0.79   2.63   1.31   0.84   2.05   0.82   0.60   1.12
  24   Weakness                           1.19                0.58   2.46   1.32   0.80   2.17   1.37   0.94   2.00   0.92   0.68   1.23

CI, confidence interval; N/A, not applicable.

In summary, although an association between HPV vaccination and symptoms was not observed in the population with a high healthy vaccine effect bias (e.g. 17--21 year old group), an association between HPV vaccination and some characteristic symptoms was observed in those populations with a low healthy vaccine effect bias (e.g. 15‐, 16‐, and 15--16 year old groups). These findings suggest that HPV vaccination could lead to significant side‐effects, such as memory impairment, dyscalculia, and involuntary movement.

### *Unadjusted odds ratios provided by analyses comparing the vaccinated cases in all age groups with the unvaccinated controls in the 15--16 year old group* {#jjns12252-sec-0021}

The unadjusted ORs of the events for all 24 symptoms among 26,517 women, comparing the vaccinated cases (20,748 women) in all age groups with the unvaccinated controls (5769 women) in the 15--16 year old group, are shown in Table [6](#jjns12252-tbl-0006){ref-type="table"}. The ORs were significantly higher for the symptoms of memory impairment (OR: 1.80 \[95% CI: 1.43--2.25\]), dyscalculia (OR: 1.80 \[95% CI: 1.19--2.73\]), dyslexia (OR: 1.36 \[95% CI: 1.06--1.73\]), involuntary movement (OR: 1.82 \[95% CI: 1.21--2.73\]), walking disability (OR: 2.02 \[95% CI: 1.01--4.06\]), and a sudden attack of muscle weakness (OR: 1.39 \[95% CI: 1.03--1.88\]).

###### 

Unadjusted odds ratios (ORs) comparing the vaccinated cases in all age groups with the unvaccinated controls in the 15‐16 year old age group

  No.   Symptom                             Vaccinated   Unvaccinated   Unadjusted                       
  ----- ---------------------------------- ------------ -------------- ------------ ------ ------ ------ ------
  1     Menstrual abnormality                  3603         17,001         1399      4348  0.66   0.61   0.71
  2     Menorrhagia                            1142         19,427         325       5414  0.98   0.86   1.11
  3     Arthralgia                             1163         19,411         423       5320  0.75   0.67   0.85
  4     Severe headache                        1529         19,083         537       5226  0.78   0.70   0.86
  5     Lassitude                              1831         18,775         566       5195  0.90   0.90   0.99
  6     Exhaustion                             1867         18,734         552       5204  0.94   0.85   1.04
  7     Impaired consciousness                 1159         19,425         415       5339  0.77   0.68   0.86
  8     Abnormal visual field                  324          20,256          90       5669  1.01   0.80   1.27
  9     Severe photophobia                     720          19,881         184       5575  1.10   0.93   1.29
  10    Reduced visual acuity                  919          19,670         519       5239  0.47   0.42   0.53
  11    Dizziness                              1836         18,759         640       5119  0.78   0.71   0.86
  12    Cold sensation in the legs             1775         18,807         655       5104  0.74   0.67   0.81
  13    Sleep disorder                         1226         19,372         359       5396  0.95   0.84   1.07
  14    Hypersomnolence                        1936         18,632         622       5132  0.86   0.78   0.94
  15    Skin roughness                         1497         19,100         652       5105  0.61   0.56   0.68
  16    Hyperpnea                              536          20,075         168       5597  0.89   0.75   1.06
  17    Memory impairment                      559          20,054          88       5673  1.80   1.43   2.25
  18    Dyscalculia                            167          20,442          26       5737  1.80   1.19   2.73
  19    Dyslexia                               386          20,224          80       5686  1.36   1.06   1.73
  20    Involuntary movement                   175          20,436          27       5736  1.82   1.21   2.73
  21    Walking disability                      65          20,540          9        5745  2.02   1.01   4.06
  22    Using a cane or wheelchair              26          20,581          7        5745  1.04   0.45   2.39
  23    Sudden attack of muscle weakness       253          20,340          51       5701  1.39   1.03   1.88
  24    Weakness                               318          20,224          70       5666  1.27   0.98   1.65

CI, confidence interval.

### *Elapsed time period from the first vaccination to symptom onset* {#jjns12252-sec-0022}

The mean and median number of months between the time of the first HPV vaccination and the onset time of the symptoms are presented in Table [7](#jjns12252-tbl-0007){ref-type="table"}. The elapsed time period from the first vaccination to symptom onset ranged from 0 to 114 months. The median number of months from the first vaccination to symptom onset for the cognitive disorders was 24.0 (memory impairment), 25.0 (dyscalculia), and 30.0 (dyslexia). The median number of months for movement disorders was 20.5 (involuntary movement), 14.0 (walking disability), 17.0 (using a cane or wheelchair), 19.5 (a sudden attack of muscle weakness), and 17.0 (weakness). The median number of months for the cognitive disorders was \~10 months longer than those for the movement disorders.

###### 

Elapsed time period from the first vaccination to symptom onset

  No.   Symptom                            n 1[†](#jjns12252-note-0012){ref-type="fn"}   n 2[‡](#jjns12252-note-0013){ref-type="fn"}   Min.   Max.   Mean   (SD)     Median   (IQR)
  ----- ---------------------------------- --------------------------------------------- --------------------------------------------- ------ ------ ------ -------- -------- --------------
  1     Menstrual abnormality              3603                                          1572                                          0      113    21.7   (16.1)   19.0     (8.0--33.0)
  2     Menorrhagia                        1142                                          511                                           0      60     21.7   (15.7)   19.0     (8.0--34.0)
  3     Arthralgia                         1163                                          500                                           0      63     18.2   (16.4)   14.0     (3.1--31.0)
  4     Severe headache                    1529                                          646                                           0      64     20.6   (15.6)   18.0     (7.0--31.0)
  5     Lassitude                          1831                                          707                                           0      114    19.6   (15.7)   17.0     (6.0--30.0)
  6     Exhaustion                         1867                                          742                                           0      114    21.7   (15.8)   20.0     (8.0--33.0)
  7     Impaired consciousness             1159                                          439                                           0      64     20.8   (15.8)   17.0     (7.0--32.0)
  8     Abnormal visual field              324                                           148                                           0      57     22.5   (15.8)   20.0     (9.0--33.0)
  9     Severe photophobia                 720                                           261                                           0      64     23.1   (16.7)   21.0     (8.0--37.0)
  10    Reduced visual acuity              919                                           479                                           0      63     20.7   (14.7)   18.0     (9.0--30.0)
  11    Dizziness                          1836                                          809                                           0      64     22.1   (15.8)   20.0     (9.0--35.0)
  12    Cold sensation in the legs         1775                                          384                                           0      52     15.1   (11.9)   14.0     (4.0--22.0)
  13    Sleep disorder                     1226                                          494                                           0      113    28.1   (17.7)   27.0     (13.0--42.8)
  14    Hypersomnolence                    1936                                          696                                           0      60     23.1   (15.3)   21.0     (11.0--35.0)
  15    Skin roughness                     1497                                          739                                           0      60     25.0   (16.0)   24.0     (11.0--38.0)
  16    Hyperpnea                          536                                           303                                           0      69     23.0   (15.6)   21.0     (10.0--34.0)
  17    Memory impairment                  559                                           250                                           0      63     23.5   (16.1)   24.0     (8.0--35.0)
  18    Dyscalculia                        167                                           76                                            0      54     23.3   (16.3)   25.0     (7.8--35.0)
  19    Dyslexia                           386                                           154                                           0      60     28.9   (16.0)   30.0     (16.0--41.5)
  20    Involuntary movement               175                                           96                                            0      61     23.0   (16.3)   20.5     (9.0--36.5)
  21    Walking disability                 65                                            41                                            0      55     17.6   (15.8)   14.0     (5.0--25.0)
  22    Using a cane or wheelchair         26                                            15                                            1      54     21.3   (17.4)   17.0     (7.0--30.0)
  23    Sudden attack of muscle weakness   253                                           118                                           0      56     21.9   (16.1)   19.5     (7.3--35.0)
  24    Weakness                           318                                           170                                           0      57     20.7   (16.6)   17.0     (6.0--35.0)

Number of patients with symptoms;

the number of patients of which the onset time was available.

CI, confidence interval; IQR, interquartile range; SD, standard deviation.

DISCUSSION {#jjns12252-sec-0023}
==========

Adverse events following human papilloma virus vaccination {#jjns12252-sec-0024}
----------------------------------------------------------

### *Healthy user bias, another form of selection bias, and the effect of an imbalance in the study period* {#jjns12252-sec-0025}

The unadjusted ORs were \<1 for almost all the symptoms that were common in the adolescents, such as menstrual abnormality, lassitude, and dizziness, suggesting that HPV vaccination can reduce the risk of symptoms. However, two types of hypotheses concerning these relatively low ORs can be made. First, one possible explanation for these findings is the healthy vaccine effect bias (Fine & Chen, [1992](#jjns12252-bib-0006){ref-type="ref"}; Shrank, Patrick, & Brookhart, [2011](#jjns12252-bib-0018){ref-type="ref"}). These common symptoms are more prone to the healthy vaccine effect. For instance, young women in better health might be more likely to be vaccinated and women in worse health might be less likely to receive HPV vaccination. Therefore, events in the vaccinated group might be underestimated, whereas those in the unvaccinated group might be overestimated. Consequently, when comparing the vaccinated cases with the unvaccinated controls**,** the ORs might be underestimated. As mentioned above in the section of statistical analyses, the healthy vaccine effect bias is more likely to occur the higher the vaccination rate. In fact, the ORs were \<1 for all symptoms in the 17--21 year old group and most were statistically significant. That is, the influence of the healthy vaccine effect bias was remarkably observed in the analyses of the 17--21 year old group with high vaccination coverage (\>70%).

Second, a focus on the difference in the study period between the vaccinated cases and the unvaccinated controls should be considered. As described in the Methods section, the study period was restricted for the vaccinated cases to the post‐vaccination period (range: 0--6 years) and the study period was defined for the unvaccinated controls as the complete time period of the questionnaire survey (from 12 years of age to the participant\'s age at September, 2015; range: 3--9 years). Consequently, the mean study period for the vaccinated cases was shorter than that for the unvaccinated controls. As a result of this difference, the event rates of the vaccinated cases were expected to be relatively underestimated, compared to those of the unvaccinated controls.

### *Multivariate analysis: Age‐adjustment and study period adjustment* {#jjns12252-sec-0026}

In contrast to the common symptoms in adolescents, the unadjusted ORs were \>1 for distinct symptoms, including memory impairment, involuntary movement, walking disability, a sudden attack of muscle weakness, and weakness (Tables [2](#jjns12252-tbl-0002){ref-type="table"} and [3](#jjns12252-tbl-0003){ref-type="table"}). Moreover, in the multivariate analysis, the study period‐adjusted ORs for memory impairment, dyscalculia, involuntary movement, walking disability, a sudden attack of muscle weakness, and weakness were \>1 and the ORs for memory impairment and involuntary movement were statistically significant, although they were not adjusted for multiplicity (Table [3](#jjns12252-tbl-0003){ref-type="table"}). These findings are consistent with those of Yokota *et al.* ([2015](#jjns12252-bib-0022){ref-type="ref"}), who proposed the assumption that the HPV vaccine might develop hypothalamic damage, resulting in the onset of cognitive impairment or movement disorders.

In general, epidemiological research uses age adjustment to reduce the effect of having older participants in one group, compared to another group that has younger participants. However, an alternative covariate "study period" (defined by the post‐vaccination period for the vaccinated cases and the complete period of the questionnaire survey period for the unvaccinated controls) was considered, apart from age.

When conducting a logistic regression analysis in the model without an interaction, there was a need to confirm which of the following assumptions were made in the analysis of the data from the study: (i) the covariate (age or study period) can be a confounder: (ii) the distribution of the covariate differs between the two groups (vaccinated cases and unvaccinated controls); (iii) the linearity between the covariate and events and similarity between the vaccinated cases and the unvaccinated controls are observed; and (iv) the test for an interaction between vaccination and the covariate is not statistically significant.

As for age adjustment, the data from the present study met only assumption (ii). With respect to a confounder (assumption (i)), the data did not meet the assumption. That is because, considering the participants in the present study are young women ranging in age from 15 to 21 years, it is unnatural that the risk of the disease is naturally higher in the older participants, compared to the younger ones, in terms of the target symptoms in the study. As mentioned above in the Results section, there was neither a linear association between age and the event rates nor a similar effect of age on an event between the vaccinated cases and the unvaccinated controls. Furthermore, the test for the interaction between vaccination and age was statistically significant for almost all of the symptoms. These results supported the concept that the logistic regression model with age as the only covariate did not fit the data of this study. This is thought to explain why almost all the symptoms demonstrated ORs of \<1 and most of them were statistically significant.

In contrast, the covariate "study period" can be a confounder because it refers to the risk period in which the event (the experience of symptom) occurs. That is, the longer the risk period, the more likely the participants are to have experienced symptoms. The distribution of the study period differed between the vaccinated cases and the unvaccinated controls. There was no linear association between the study period and event rates and no similar effect of the study period on an event between the vaccinated cases and the unvaccinated controls. The test for an interaction between vaccination and the study period was not statistically significant, except for seven symptoms (Table [3](#jjns12252-tbl-0003){ref-type="table"}). As above‐mentioned, the logistic regression model with the study period as a covariate did not always fit the data from the present study. However, it can at least be stated that, in the case of the logistic regression, it appears more reasonable to assume that the study period is more appropriate than age as a covariate.

Suzuki and Hosono ([2018](#jjns12252-bib-0020){ref-type="ref"}) reported the age‐adjusted ORs of the association of vaccination and the occurrence of symptoms as primary outcomes, in which almost all the symptoms demonstrated ORs of \< 1 and most of them were statistically significant. These results should be interpreted with caution. The reason is as follows. They described that age confounded the association between HPV vaccination and the reported symptoms. Therefore, they decided all the analyses should be age‐adjusted, although they did not provide any details of the methods, such as considering and examining the confounders or exploring the data distribution.

As a supplementary analysis, the possible associations between HPV vaccination and each symptom were explored by using standardization with the reference group of the whole participants to estimate the age‐standardized RR with 95% CIs (Sato, [1994](#jjns12252-bib-0017){ref-type="ref"}). Table [8](#jjns12252-tbl-0008){ref-type="table"} summarizes the age‐standardized RRs for all 24 symptoms among 29,846 women. All the symptoms demonstrated RRs of \<1 and most of them were statistically significant. These findings raise the possibility that there was no association between HPV vaccination and the symptoms (Table [8](#jjns12252-tbl-0008){ref-type="table"}). In this regard, however, it is noted that the RR varied and did not show the same direction across the age strata for almost all the symptoms; hence, standardization does not fit the data from the present study.

###### 

Age‐standardized risk ratios (RRs) in all age groups

  No.   Symptom                             Vaccinated   Unvaccinated   Unadjusted   Age‐standardized                                     
  ----- ---------------------------------- ------------ -------------- ------------ ------------------ ------ ------ ------ ------ ------ ------
  1     Menstrual abnormality                  3603         17,001         2309            6696        0.68   0.65   0.71   0.63   0.60   0.67
  2     Menorrhagia                            1142         19,427         560             8434        0.89   0.81   0.98   0.78   0.69   0.88
  3     Arthralgia                             1163         19,411         720             8276        0.71   0.65   0.77   0.63   0.57   0.71
  4     Severe headache                        1529         19,083         925             8097        0.72   0.67   0.78   0.64   0.58   0.70
  5     Lassitude                              1831         18,775         1037            7984        0.77   0.72   0.83   0.65   0.59   0.71
  6     Exhaustion                             1867         18,734         991             8028        0.82   0.77   0.89   0.71   0.65   0.78
  7     Impaired consciousness                 1159         19,425         723             8294        0.70   0.64   0.77   0.65   0.58   0.72
  8     Abnormal visual field                  324          20,256         172             8845        0.83   0.69   0.99   0.65   0.52   0.82
  9     Severe photophobia                     720          19,881         356             8662        0.89   0.78   1.00   0.67   0.57   0.78
  10    Reduced visual acuity                  919          19,670         794             8221        0.51   0.46   0.56   0.51   0.45   0.57
  11    Dizziness                              1836         18,759         1089            7927        0.74   0.69   0.79   0.67   0.61   0.73
  12    Cold sensation in the legs             1775         18,807         1144            7873        0.68   0.63   0.73   0.57   0.52   0.62
  13    Sleep disorder                         1226         19,372         692             8320        0.78   0.71   0.85   0.59   0.52   0.65
  14    Hypersomnolence                        1936         18,632         1058            7955        0.80   0.75   0.86   0.70   0.64   0.76
  15    Skin roughness                         1497         19,100         1062            7950        0.62   0.57   0.66   0.58   0.52   0.63
  16    Hyperpnea                              536          20,075         335             8694        0.70   0.61   0.80   0.54   0.46   0.64
  17    Memory impairment                      559          20,054         217             8805        1.13   0.97   1.32   0.81   0.67   0.97
  18    Dyscalculia                            167          20,442          79             8940        0.93   0.71   1.21   0.59   0.43   0.82
  19    Dyslexia                               386          20,224         181             8846        0.93   0.78   1.11   0.63   0.51   0.79
  20    Involuntary movement                   175          20,436          58             8964        1.32   0.98   1.78   0.90   0.63   1.29
  21    Walking disability                      65          20,540          22             8990        1.29   0.80   2.09   0.74   0.41   1.31
  22    Using a cane or wheelchair              26          20,581          16             8994        0.71   0.38   1.32   0.40   0.19   0.82
  23    Sudden attack of muscle weakness       253          20,340         100             8909        1.11   0.88   1.39   0.78   0.58   1.03
  24    Weakness                               318          20,224         124             8862        1.12   0.91   1.38   0.94   0.72   1.22

CI, confidence interval.

### *Age‐stratified analysis considering the effect of the healthy user* {#jjns12252-sec-0027}

Most of the vaccinated women in all age groups generally were considered to be healthy women because they were healthy vaccine users. The women in the 15--16 year old group had reached the age of the target population for HPV vaccination after suspension of the government recommendation. Thus, almost all the women in this age group were expected to be unvaccinated simply because they did not want to be vaccinated, not because of health issues. Given this information*,* it was assumed that the unvaccinated controls in the 15--16 year old group were generally healthy. In order to minimize the impact of the healthy user bias, the vaccinated cases in all age groups were compared with the unvaccinated controls in the 15--16 year old group. The ORs were significantly higher for the symptoms of memory impairment, dyscalculia, dyslexia, involuntary movement, walking disability, and a sudden attack of muscle weakness. These findings suggested that HPV vaccination might cause significant health problems, which can impair learning and have a negative impact on daily life.

Limitations of the present study and suggestions for further research {#jjns12252-sec-0028}
---------------------------------------------------------------------

The validity of the findings from the questionnaire surveys is dependent on adequate response rates. The response rate of the Nagoya Survey was moderate, at 43% (30,793/71,177); thus, the findings of the present study should be considered in light of this limitation. Moreover, another potential limitation of the present study is that differential misreporting or misclassification bias, as well as the characteristic symptom development in a multilayered manner, were not evaluated.

Further large‐scale and well‐designed (careful consideration should be given to the characteristics of post‐HPV vaccination symptoms) cohort studies are warranted to confirm the causal relationship between HPV vaccination and the occurrence of possible adverse events, as suggested by the current exploratory analyses.

CONCLUSION {#jjns12252-sec-0029}
==========

Based on this analysis using data from the Nagoya Survey, a possible association between HPV vaccination and distinct symptoms, such as cognitive impairment or movement disorders, exists. A consistent causal relationship between HPV vaccination and these symptoms remains uncertain. However, given the seriousness of the symptoms, the authors believe that a more comprehensive and large‐scale study is essential to confirm the safety of HPV vaccination.
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